Sun Forwards Specialty Strategy With $576m Concert Acquisition
Sun’s Nabs Concert, Picking Up Firm’s ‘Potential Best-In-Class’ Deuruxolitinib
Executive Summary
Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.
You may also be interested in...
Sun Pharma Reinforces Position As Indian Industry Leader
Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.
The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
Concert’s Patient-Reported Outcome Could Help Differentiate Its Alopecia Therapy
Concert’s CTP-543 would be second or third to market in alopecia areata, behind Lilly and likely Pfizer, but the biotech thinks its drug will have the best profile based on efficacy and patient satisfaction.